Presidio Property Trust, Inc.
Business
Presidio Property Trust, Inc. is an internally-managed real estate investment trust that acquires, owns, manages and leases commercial properties and model homes. It offers leasing of office and industrial space, sale‑leaseback (triple‑net) model homes to homebuilders, property management, and advisory services for affiliated partnerships. Its operations are organized around two principal businesses: Office/Industrial Properties and PPT Model Homes, supported by DownREITs, limited partnerships and a wholly owned model home corporation. The company operates properties in Colorado, North Dakota, California, Maryland and Texas, with model homes in Texas, Florida and Arizona, and distributes space through direct leasing, affiliated partnerships and third‑party property managers.
Summary from filing dated 2025-03-31
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Rental income | 16 | 19 | 17 | 17 | 18 | |
| Fees and other income | 343,790 | 401,462 | 243,217 | 560,971 | 810,852 | |
| Total revenue | 17 | 19 | 18 | 18 | 19 | |
| Rental operating costs | 6 | 6 | 6 | 6 | 6 | |
| General and administrative | 6 | 8 | 7 | 6 | 6 | |
| Depreciation and amortization | 5 | 6 | 5 | 6 | 5 | |
| Asset Impairment Charges | 6 | 2 | 3 | 0 | — | |
| Total costs and expenses | 23 | 21 | 21 | — | — | |
| Interest and other income, net | 20,881 | −151,356 | 1 | 21,075 | −42,845 | |
| Gain on sales of real estate, net | 5 | 3 | 3 | — | — | |
| Net loss in Conduit Pharmaceuticals marketable securities (see footnote 9) | −188,287 | −18 | −23 | — | — | |
| Income tax (expense) benefit | −463,170 | −60,855 | 335,780 | −1 | 47,620 | |
| Total loss, net | −1 | −21 | 17 | 1 | −2 | |
| Net loss: | −8 | −23 | 13 | 1 | −1 | |
| Less: Income attributable to noncontrolling interests | −685,586 | −3 | −3 | −4 | −2 | |
| Net loss attributable to Presidio Property Trust, Inc. stockholders | −8 | −26 | 10 | −2 | −4 | |
| Less: Preferred Stock Series D dividends | −2 | −2 | −2 | −2 | −1 | |
| Net loss attributable to Presidio Property Trust, Inc. common stockholders | −11 | −28 | 8 | −7 | −5 | |
| Basic & Diluted (in dollars per share) | −8.65 | −22.5 | 0.68 | −0.57 | −0.46 | |
| Weighted average number of common shares outstanding - basic & dilutive (in shares) | 1 | 1 | 12 | 12 | 10 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Land | 16 | 16 | 22 | 19 | 21 | |
| Buildings and improvements | 102 | 103 | 134 | 126 | 119 | |
| Tenant improvements | 18 | 16 | 18 | 14 | 13 | |
| Lease intangibles | 3 | 4 | 4 | 4 | 4 | |
| Real estate assets and lease intangibles held for investment, cost | 139 | 139 | 177 | 163 | 157 | |
| Accumulated depreciation and amortization | −38 | −34 | −39 | −35 | −31 | |
| Real estate assets and lease intangibles held for investment, net | 102 | 105 | 139 | 128 | 127 | |
| Real estate assets held for sale, net | 7 | 22 | 5 | 2 | 11 | |
| Real estate assets, net | 109 | 128 | 144 | 131 | 138 | |
| Cash, cash equivalents and restricted cash | 7 | 8 | 7 | 17 | 15 | |
| Deferred leasing costs, net | 1 | 2 | 2 | 2 | 1 | |
| Goodwill | 1 | 1 | 2 | 2 | 2 | |
| Investment in Conduit Pharmaceuticals marketable securities (see Notes 2 & 9) | 3,900 | 206,177 | 18 | 0 | — | |
| Deferred tax asset | 223,388 | 298,645 | 346,762 | 0 | — | |
| Other Assets, Miscellaneous | 3 | 3 | 3 | 4 | 5 | |
| Total other assets | 13 | 15 | 32 | 24 | 23 | |
| TOTAL ASSETS | 122 | 143 | 176 | 291 | 161 | |
| Mortgage notes payable, net | 82 | 81 | 104 | 96 | 87 | |
| Mortgage notes payable related to properties held for sale, net | 10 | 21 | 4 | 999,523 | 2 | |
| Mortgage notes payable, total net | 92 | 102 | 108 | 97 | 89 | |
| Accounts payable and accrued liabilities | 3 | 3 | 5 | 4 | 5 | |
| Accrued real estate taxes | 2 | 2 | 2 | 2 | 2 | |
| Dividends payable - Preferred Stock Series D | 190,220 | 194,784 | 174,011 | 178,511 | 179,685 | |
| Lease liability, net | 40,108 | 64,345 | 16,086 | 46,833 | 75,547 | |
| Below-market leases, net | 3,316 | 8,625 | 13,266 | 18,240 | 73,130 | |
| Total liabilities | 97 | 108 | 115 | 108 | 96 | |
| Commitments and contingencies (see Note 10) | — | — | — | — | — | |
| Additional paid-in capital | 187 | 186 | 182 | 182 | 186 | |
| Dividends and accumulated losses | −170 | −159 | −132 | −138 | −131 | |
| Total stockholders' equity before noncontrolling interest | 17 | 27 | 51 | 44 | 56 | |
| Noncontrolling interest | 8 | 8 | 10 | 9 | 10 | |
| Total equity | 25 | 35 | 61 | 53 | 65 | |
| TOTAL LIABILITIES AND EQUITY | 122 | 143 | 176 | 291 | 161 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation and amortization | 5 | 6 | — | — | — | |
| Stock compensation | 1 | 1 | 989,515 | 1 | 2 | |
| Employee Bonuses paid with CDT stock | 0 | 172,421 | 0 | — | — | |
| Amortization of financing costs | 281,245 | 351,291 | 345,880 | 240,090 | 479,853 | |
| Amortization of below-market leases | −4,753 | −4,641 | −4,974 | −54,890 | −60,203 | |
| Straight-line rent adjustment | 261,483 | −152,722 | −332,055 | −252,759 | −231,577 | |
| Other assets | 355,913 | 82,575 | −211,023 | 1 | 190,354 | |
| Deferred tax asset | 75,257 | 48,117 | −346,762 | 0 | — | |
| Accounts payable and accrued liabilities | 186,636 | −1 | 11,546 | −2 | −1 | |
| Deferred leasing costs | −148,148 | −502,946 | — | — | — | |
| Accrued real estate taxes | −187,448 | 19,390 | 73,212 | −61,038 | −607,773 | |
| Net cash provided by (used in) operating activities | 417,870 | −728,060 | 1 | 928,817 | 2 | |
| Real estate acquisitions | −9 | −10 | −22 | −16 | −22 | |
| Additions to buildings and tenant improvements | −3 | −2 | −6 | −2 | −2 | |
| Investment in marketable securities | 0 | −2,362 | −2 | −2 | −4 | |
| Proceeds from sale of marketable securities | 13,990 | 105,206 | 3 | 2 | 2 | |
| Proceeds from sales of real estate, net | 26 | 25 | 11 | 26 | 50 | |
| Net cash provided by investing activities | 13 | 13 | 121 | −126 | 24 | |
| Proceeds from mortgage notes payable, net of issuance costs | 19 | 22 | 21 | 20 | 12 | |
| Payment of debt issuance costs | −424,002 | −335,724 | −246,557 | −3 | −572,458 | |
| Repayment of mortgage notes payable | −29 | −28 | −10 | −12 | −43 | |
| Payment of deferred offering costs | −343,514 | 0 | −5,000 | — | — | |
| Distributions to noncontrolling interests | −1 | −4 | −4 | — | — | |
| Contributions from noncontrolling interests | 0 | 200,000 | 3 | — | — | |
| Dividends paid to Series D Preferred Stockholders | −2 | −2 | −2 | −2 | −994,263 | |
| Net cash used in financing activities | −15 | −11 | −132 | 127 | −23 | |
| Net (decrease) increase in cash equivalents and restricted cash | −614,137 | 2 | −10 | 2 | 3 | |
| Income taxes paid | 78,848 | 46,511 | 533,340 | — | — | |
| Paid building and tenant improvements from prior year | −207,847 | −295,567 | — | — | — | |
| Private warrants from Conduit Pharmaceuticals | 0 | 642,600 | 0 | — | — | |
| Unpaid deferred offering costs | 6,589 | 0 | — | 0 | 15,449 | |
| Unpaid building and tenant improvements | 361,261 | 207,847 | 295,567 | — | — |